よむ、つかう、まなぶ。
07 参考資料２－１ 帯状疱疹ワクチン ファクトシート (55 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_36248.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第21回 11／9）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
146. Liu XC, Simmonds KA, Russell ML, Svenson LW. Herpes zoster vaccine (HZV):
utilization and coverage 2009 - 2013, Alberta, Canada. BMC Public Health 2014; 14: 1098
147. Australian Government Department of Health. Shingles vaccine Zostavax® to be provided
free for 70-79 year olds from November 2016. Available:
http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/news-20152307
148. ECDC. Vaccine Schedule Available:
http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx
149. Gov.UK. Shingles vaccination. Available:
http://www.nhs.uk/conditions/vaccinations/Pages/shingles-vaccination.aspx
150. PR Newswire. French National Health Authority Recommends Routine Vaccination with
Zostavax® to Protect Seniors Against Shingles Available:
http://www.prnewswire.co.uk/news-releases/french-national-health-authority-recommendsroutine-vaccination-with-zostavax-to-protect-seniors-against-shingles-236331421.html
151. National Health Care Institute. ZOSTAVAX for the prevention of herpes zoster and
postherpetic neuralgia. Available:
https://www.zorginstituutnederland.nl/binaries/content/documents/zinl-www/documenten/p
ublicaties/publications-in-english/2013/1309-zostavax-for-the-prevention-of-herpes-zosterand-postherpetic-neuralgia/Zostavax+for+the+prevention+of+Herpes+Zoster+and+Posther
petic+Neuralgia+(EUnetHTA).pdf
152. Horn J, Karch A, Damm O, Kretzschmar ME, Siedler A, Ultsch B, Weidemann F, Wichmann
O, Hengel H, Greiner W, Mikolajczyk RT. Current and future effects of varicella and herpes
zoster vaccination in Germany - Insights from a mathematical model in a country with
universal varicella vaccination. Hum Vaccin Immunother. 2016; 12(7): 1766-76.
153. Préaud
E, Uhart
M, Böhm
K, Aidelsburger
P, Anger
D, Bianic
F, Largeron
N.
Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster
and post-herpetic neuralgia in adults aged 50 and over in Germany. Hum Vaccin
Immunother 2015; 11: 884-96.
154. Choi W. S. Herpes zoster vaccine in Korea. Clin Exp Vaccine Res 2013; 2: 92-6.
155. WHO. Herpes zoster vaccines. Available:
http://www.who.int/immunization/sage/meetings/2014/april/2_Background_document_Her
pes_Zoster.pdf
156. Paganino C, Alicino C, Trucchi C, Albanese E, Sticchi L, Icardi G. Herpes zoster: the
rationale for the introduction of vaccination in Italy. J Prev Med Hyg 2015; 56: E33-6.
157. Lopez-Belmonte JL, Cisterna R, Gil de Miguel A, Guilmet C, Bianic F, Uhart M. The use
of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and
older. J Med Econ 2016; 19: 576-86.
50
utilization and coverage 2009 - 2013, Alberta, Canada. BMC Public Health 2014; 14: 1098
147. Australian Government Department of Health. Shingles vaccine Zostavax® to be provided
free for 70-79 year olds from November 2016. Available:
http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/news-20152307
148. ECDC. Vaccine Schedule Available:
http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx
149. Gov.UK. Shingles vaccination. Available:
http://www.nhs.uk/conditions/vaccinations/Pages/shingles-vaccination.aspx
150. PR Newswire. French National Health Authority Recommends Routine Vaccination with
Zostavax® to Protect Seniors Against Shingles Available:
http://www.prnewswire.co.uk/news-releases/french-national-health-authority-recommendsroutine-vaccination-with-zostavax-to-protect-seniors-against-shingles-236331421.html
151. National Health Care Institute. ZOSTAVAX for the prevention of herpes zoster and
postherpetic neuralgia. Available:
https://www.zorginstituutnederland.nl/binaries/content/documents/zinl-www/documenten/p
ublicaties/publications-in-english/2013/1309-zostavax-for-the-prevention-of-herpes-zosterand-postherpetic-neuralgia/Zostavax+for+the+prevention+of+Herpes+Zoster+and+Posther
petic+Neuralgia+(EUnetHTA).pdf
152. Horn J, Karch A, Damm O, Kretzschmar ME, Siedler A, Ultsch B, Weidemann F, Wichmann
O, Hengel H, Greiner W, Mikolajczyk RT. Current and future effects of varicella and herpes
zoster vaccination in Germany - Insights from a mathematical model in a country with
universal varicella vaccination. Hum Vaccin Immunother. 2016; 12(7): 1766-76.
153. Préaud
E, Uhart
M, Böhm
K, Aidelsburger
P, Anger
D, Bianic
F, Largeron
N.
Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster
and post-herpetic neuralgia in adults aged 50 and over in Germany. Hum Vaccin
Immunother 2015; 11: 884-96.
154. Choi W. S. Herpes zoster vaccine in Korea. Clin Exp Vaccine Res 2013; 2: 92-6.
155. WHO. Herpes zoster vaccines. Available:
http://www.who.int/immunization/sage/meetings/2014/april/2_Background_document_Her
pes_Zoster.pdf
156. Paganino C, Alicino C, Trucchi C, Albanese E, Sticchi L, Icardi G. Herpes zoster: the
rationale for the introduction of vaccination in Italy. J Prev Med Hyg 2015; 56: E33-6.
157. Lopez-Belmonte JL, Cisterna R, Gil de Miguel A, Guilmet C, Bianic F, Uhart M. The use
of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and
older. J Med Econ 2016; 19: 576-86.
50